fashion -WSS

fashion

author：focus 2025-10-01 10:57:59 - browse：894

A collage illustration with a patient in the center with a hand to the left administering treatment and a doctor in the background. -- health tech coverage from STAT — Katy Lemay for STAT

The makers of minimally invasive surgical devices seemed poised to capture a wide swath of the obesity treatment market. Patients needed an option that lay between the two treatment extremes: cutting open the abdomen to perform permanent bariatric surgery, or changing your diet or exercise routine.

Then, a new class of weight loss medications that successfully mimic the feeling of fullness hit the market, and the landscape changed.

“It turns out that what came along — before those endoscopic devices have really matured — is these new drugs,” said Lee Kaplan, director of Massachusetts General’s obesity institute. Since the Food and Drug Administration approved Novo Nordisk’s Wegovy in 2021, it and similar drugs that followed have swiftly captured the public’s interest — and are on their way to generating billions of dollars in sales.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： 2023 Nobel Prize in Medicine goes to Karikó and Weissman

leisure time

WSS

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Some top drug companies are starting to take action on climate

Bristol Myers buys into radiopharmaceuticals with RayzeBio

CRISPR gene editing developments we’re watching in 2024

Hospitals owned by private equity see complications spike 25%

Albert Bourla of Pfizer: worst biopharma CEO of 2023

focus

fashion

focus

Activists slam private health insurers over coverage restrictions

CDC picks Alphabet's Verily for wasterwater surveillance contract

Novavax promises a turnaround & Lilly roils the obesity market

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Congress extends some pandemic preparedness programs

At least 13 dead in Texas as scorching temps continue

The biotech scorecard for Q4: 16 stock

Jerome Adams on the need for new antivirals for Covid

Prime Medicine, Myeloid Therapeutics clash over genome

hotspot

Readout Newsletter: The latest on Moderna, Apellis, and Merck

WHO recommends second malaria vaccine

CDC picks Alphabet's Verily for wasterwater surveillance contract

CRISPR gene editing developments we’re watching in 2024

Editas, Vertex strike deal on CRISPR

IVG is promising — but it won’t replace IVF quite yet

entertainment

leisure time

explore

hotspot